313 related articles for article (PubMed ID: 32775974)
1. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease.
Sinha R; Lockman KA; Homer NZM; Bower E; Brinkman P; Knobel HH; Fallowfield JA; Jaap AJ; Hayes PC; Plevris JN
JHEP Rep; 2020 Oct; 2(5):100137. PubMed ID: 32775974
[TBL] [Abstract][Full Text] [Related]
2. Volatile Biomarkers in Breath Associated With Liver Cirrhosis - Comparisons of Pre- and Post-liver Transplant Breath Samples.
Fernández Del Río R; O'Hara ME; Holt A; Pemberton P; Shah T; Whitehouse T; Mayhew CA
EBioMedicine; 2015 Sep; 2(9):1243-50. PubMed ID: 26501124
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
4. (
Molina-Molina E; Shanmugam H; Di Ciaula A; Grattagliano I; Di Palo DM; Palmieri VO; Portincasa P
JHEP Rep; 2021 Feb; 3(1):100203. PubMed ID: 33490935
[TBL] [Abstract][Full Text] [Related]
5. Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence.
Cozzolino R; De Giulio B; Martignetti A; Forte G; Dallio M; Romeo M; Scognamiglio F; Ventriglia L; Stocchero M; Federico A
Metabolomics; 2022 Nov; 18(12):98. PubMed ID: 36441279
[TBL] [Abstract][Full Text] [Related]
6. The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.
Ahmed HS; Gangasani N; Jayanna MB; Long MT; Sanchez A; Murali AR
J Clin Exp Hepatol; 2023; 13(2):233-240. PubMed ID: 36950488
[TBL] [Abstract][Full Text] [Related]
7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome.
Shaji N; Singhai A; Sarawagi R; Pakhare AP; Mishra VN; Joshi R
Cureus; 2022 Feb; 14(2):e22682. PubMed ID: 35386158
[TBL] [Abstract][Full Text] [Related]
9. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
Arasaradnam RP; McFarlane M; Daulton E; Westenbrink E; O'Connell N; Wurie S; Nwokolo CU; Bardhan KD; Savage RS; Covington JA
J Gastrointestin Liver Dis; 2015 Jun; 24(2):197-201. PubMed ID: 26114180
[TBL] [Abstract][Full Text] [Related]
11. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.
Erhardtsen E; Rasmussen DGK; Frederiksen P; Leeming DJ; Shevell D; Gluud LL; Karsdal MA; Aithal GP; Schattenberg JM
JHEP Rep; 2021 Aug; 3(4):100317. PubMed ID: 34466796
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.
Anand A; Singh AA; Elhence A; Vaishnav M; Biswas S; Gunjan D; Gamanagatti SR; Nayak B; Kumar R; Shalimar
J Clin Exp Hepatol; 2022; 12(2):362-371. PubMed ID: 35535086
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
[TBL] [Abstract][Full Text] [Related]
14. Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease.
Mandal A; Bhattarai B; Kafle P; Khalid M; Jonnadula SK; Lamicchane J; Kanth R; Gayam V
Cureus; 2018 Nov; 10(11):e3626. PubMed ID: 30697502
[TBL] [Abstract][Full Text] [Related]
15. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
Angelini G; Panunzi S; Castagneto-Gissey L; Pellicanò F; De Gaetano A; Pompili M; Riccardi L; Garcovich M; Raffaelli M; Ciccoritti L; Verrastro O; Russo MF; Vecchio FM; Casella G; Casella-Mariolo J; Papa L; Marini PL; Rubino F; le Roux CW; Bornstein S; Mingrone G
Gut; 2023 Feb; 72(2):392-403. PubMed ID: 35820779
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis.
Kang YW; Baek YH; Lee JH; Roh YH; Kwon HJ; Moon SY; Son MK; Jeong JS
Diagnostics (Basel); 2024 May; 14(11):. PubMed ID: 38893610
[TBL] [Abstract][Full Text] [Related]
17. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
[TBL] [Abstract][Full Text] [Related]
18. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children.
Alkhouri N; Cikach F; Eng K; Moses J; Patel N; Yan C; Hanouneh I; Grove D; Lopez R; Dweik R
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):82-7. PubMed ID: 24284369
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
20. Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population.
Qiu J; Kuang M; He S; Yu C; Wang C; Huang X; Sheng G; Zou Y
Front Endocrinol (Lausanne); 2023; 14():1302322. PubMed ID: 38125795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
